Scrip Awards 2018 Shortlist

Masters Specialty Pharma's Best Company in an Emerging Market Award

Beximco Pharmaceuticals

Biocon

CinnaGen Pharmaceutical Group

Hutchison China MediTech (Chi-Med)

Mundipharma Singapore

WuXi Biologics

Best Contract Research Organization – Full-Service Providers

CMIC Group

Covance

ICON

IQVIA

PAREXEL

Worldwide Clinical Trials

Best Contract Research Organization – Specialist Providers

Cytel

Illingworth Research Group

PHASTAR

Quanticate

Simbec-Orion

Tioga Research

Best Technological Development in Clinical Trials - Clinical Sponsor-focused

Cytel’s OK GO software

Novartis’s Nerve Live

Covance’s Xcellerate CRA Dashboard

PAREXEL’s Perceptive Cloud

IQVIA’s Mobile SVR application

ICON’s FIRECREST Pre-Screen

Phesi’s real-time data collection and analysis

CluePoints’ Intelligent Central Statistical Monitoring Solution

Bioclinica’s Bioclinica Clinical Adjudication

ERT’s Advanced Imaging Technology Solution

Ergomed/PrimeVigilance/Automation Anywhere’s robotic process automation software

Medidata’s Medidata Rave Engage

Community Partnership of the Year Award – Sponsored by Medidata Solutions

AstraZeneca’s Mentoring Team

Beximco Pharma with DSM Nutritional Products and Sight & Life Global Nutrition Research Institute to improve nutrition in rural Bangladesh

IQVIA India’s Race for 7 with the Organization for Rare Diseases India

Oxford PharmaGenesis’ Open Pharma

Best Use of Real-World Evidence

Biogen/ICON’s New insights into the burden and costs of multiple sclerosis in Europe

ICON/Vertex’s study of lumacaftor/ivacaftor lung function decline in patients with cystic fibrosis

IQVIA/Bristol-Myers Squibb’s I-O Optimise collaboration in patients with a thoracic malignancy

PAREXEL, EMD Serono (a business of Merck KGaA, Darmstadtr, Germany), MedCodeWorld, and Intermountain Healthcare's Multiple Sclerosis Algorithms Development and Validation project

Neurocrine BioSciences’s RE-KINECT prospective real-world dyskinesia screening study and registry in patients taking antipsychotics

Best Partnership Alliance

Bicycle Therapeutics and Bioverativ for hemophilia and sickle cell disease using bi-cyclic peptides

Evotec and Sanofi's strategic collaboration to establish a new open innovation platform

F-star and Denali Therapeutics to develop a multi-specific platform for delivery of medicines across the blood-brain barrier

Neurocrine and AbbVie for elagolix in women’s health

Roche and Ionis Pharmaceuticals to develop antisense drugs for Huntington's disease

Novartis and the University of Pennsylvania for CAR-T medications in pediatric cancer patients

Financing Deal of the Year – Public

InflaRx’s $100m IPO and secondary offering

resTORbio’s $163m Series A to IPO

Polyphor’s CHF165m IPO

Horizon Discovery Group’s £80m public placing

Ablynx’s $200m US IPO on NASDAQ

Morphosys’ $239m overallotment issue and NASDAQ listing

Financing Deal of the Year – Private

Crescendo Biologics' $70m Series B financing

Enterprise Therapeutics’ £29m ($41m) Series B financing

BioNTech’s $270m Series A financing

AstraZeneca/MedImmune’s $250m financing for spin-out Viela Bio

PhoreMost’s £11m ($15m) Series A financing

NodThera’s £28m Series A financing

IQVIA’s Clinical Advance of the Year Award

Ablynx’s Phase III HERCULES study of caplacizumab for acquired thrombotic thrombocytopenic purpura

Alexion Pharmaceuticals' Phase III REGAIN study of Soliris (eculizumab) in myasthenia gravis

bluebird bio’s Northstar-2 study of LentiGlobin in beta-thalassemia

GW Pharmaceuticals’ Phase III GWPCARE4 trial of Epidiolex for refractory epilepsy

Ipca Laboratories Phase IV study of hydroxychloroquine in type 2 diabetes mellitus in India

Nanobiotix’s Phase I/II trial of nanomedicine NBTXR3 in head and neck cancer

Licensing Deal of the Year – Sponsored by Worldwide Clinical Trials

AiCuris and Merck & Co (MSD) for Prevymis (letermovir) for cytomegalovirus

AstraZeneca and Merck & Co (MSD) for Lynparza and selumetinib

AstraZeneca/Pearl and Avillion for PT027 in asthma

Emergent BioSolutions and Valneva for the Zika vaccine candidate VLA1601

F-star (through F-star Delta) and Merck KGaA for five bispecific antibodies in immuno-oncology

Halozyme and Bristol-Myers Squibb for the use of ENHANZE drug delivery technology in immuno-oncology drugs

Executive of the Year – For Large & Medium Cap Companies

Edwin Moses, CEO of Ablynx

John Maraganore, CEO of Alnylam

Alan Hirzel, CEO of Abcam

Jan van de Winkle, CEO of Genmab

Vas Narasimhan, CEO of Novartis

Niels Riedemann, CEO co-founder of InflaRx

Executive of the Year – For Small Cap & Private Pharma Companies

Eduardo Bravo, CEO of TiGenix

Jurgi Camblong, CEO and founder of SOPHiA GENETICS

Carl Firth, CEO and founder of ASLAN Pharmaceuticals

Antony Loebel, executive vice president, chief medical officer, head of global clinical development of Sunovion Pharmaceuticals

Amy Schulman, CEO and co-founder of Lyndra

Raman Singh, CEO of Mundipharma  

WuXi AppTec’s Biotech Company of the Year Award

Genmab

AveXis

F-star

Neurocrine Biosciences

Bicycle Therapeutics

Diurnal Group

Business Development Team of the Year

AstraZeneca and Avillion partnership team

Bicycle Therapeutics’ business development team

CinnaGen’s business development team

Evotec’s business development team

F-star’s business development team

Rentschler Biopharma/Leukocare alliance business development team

Syneos Health's Best New Drug Award

TiGenix’s Alofisel (darvadstrocel)

Roche’s Hemlibra (emicizumab)

Novartis’s Kymriah (tisagenlecleucel)

Spark Therapeutics’ Luxturna (voretigene neparvovec-rzyl)

Kite Pharma/Gilead Sciences’ Yescarta (axicabtagene ciloleucel)